Last reviewed · How we verify
intravenous vitamin C plus thiamine
At a glance
| Generic name | intravenous vitamin C plus thiamine |
|---|---|
| Sponsor | Mansoura University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Hemorrhagic shock due to hemolysis
- Worsening of renal function
Key clinical trials
- Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock. (PHASE2)
- Steroid, Thiamine and Ascorbic Acid for Comatose Out-of-hospital Cardiac Arrest Survivors (PHASE2)
- Effects of Intravenous Metabolic Recovery Agent in Elderly Septic Patients on Prognosis and Microcirculation. (NA)
- Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock (PHASE3)
- Effects of Glucocorticoid Combined With Vitamin C and Vitamin B1 on Microcirculation in Severe Septic Shock (NA)
- Evaluation of Hydrocortisone, Vitamin C and Thiamine for the Treatment of Septic Shock (PHASE2, PHASE3)
- Effect of Anti-inflammatory and Anti-microbial Co-supplementations in Traumatic ICU Patients at High Risk of Sepsis (NA)
- Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intravenous vitamin C plus thiamine CI brief — competitive landscape report
- intravenous vitamin C plus thiamine updates RSS · CI watch RSS
- Mansoura University portfolio CI